New developments in the treatment of systemic vasculitis

Area of Science:

• Rheumatology
• Immunology
• Nephrology

Background:

• Systemic vasculitides present variable clinical severity despite diagnosis.
• Anatomical distribution and progression rate are key factors in determining immunosuppressive therapy intensity.
• Aggressive standard therapies (cyclophosphamide, glucocorticoids) carry significant risks in certain vasculitis forms.

Purpose of the Study:

• To evaluate the determinants of immunosuppressive therapy intensity in systemic vasculitis.
• To review less toxic and novel therapeutic strategies for systemic vasculitis.
• To highlight treatment-associated morbidity and relapse rates.

Main Methods:

• Review of long-term clinical course studies on systemic vasculitis.
• Analysis of treatment-associated morbidity and disease-related morbidity.
• Evaluation of novel therapeutic agents including monoclonal antibodies, enzyme inhibitors, and antivirals.

Main Results:

• Progressive pulmonary or renal disease necessitates aggressive therapy (e.g., daily cyclophosphamide, glucocorticoids).
• Chronic or indolent vasculitis forms benefit from cautious application of aggressive regimens due to high morbidity (up to 42%) and relapse rates.
• Successful alternative strategies include weekly methotrexate, monthly cyclophosphamide pulses, intravenous immunoglobulin, anti-CD4/anti-CDw52 antibodies, nafamostat mesilate, pentoxifylline, and interferon alfa.

Conclusions:

• Therapy intensity for systemic vasculitis should be tailored to disease progression and anatomical involvement.
• Less toxic therapeutic strategies offer remarkable success and improved patient outcomes.
• Novel agents show promise in managing intractable and specific forms of systemic vasculitis.